Advertisement

Obstructive lung diseases and beta-blockers: Where do we stand?

  • Author Footnotes
    1 These authors contributed equally to this manuscript.
    Helena Pité
    Correspondence
    Corresponding author at: Allergy Center, CUF-Descobertas Hospital, Rua Mário Botas, 1998-018 Lisbon, Portugal. Tel.: +351 962790162; fax: +351 210025220.
    Footnotes
    1 These authors contributed equally to this manuscript.
    Affiliations
    Allergy Center, CUF Descobertas Hospital and CUF Infante Santo Hospital, Lisbon, Portugal

    CEDOC, Chronic Diseases Research Center, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this manuscript.
    Marisa Braga da Cruz
    Footnotes
    1 These authors contributed equally to this manuscript.
    Affiliations
    Allergy Center, CUF Descobertas Hospital and CUF Infante Santo Hospital, Lisbon, Portugal
    Search for articles by this author
  • Mário Morais-Almeida
    Affiliations
    Allergy Center, CUF Descobertas Hospital and CUF Infante Santo Hospital, Lisbon, Portugal

    CINTESIS, Center for Research in Health Technologies and Information Systems, Porto, Portugal
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this manuscript.
      Cardiovascular diseases are major public health problems. ß-blockers therapy is indicated for the majority of patients with heart failure and coronary artery disease (Class I, Level of Evidence: A). These drugs are also first-line therapy for atrial fibrillation. However, ß-blocker use continues to be less than optimal, principally in patients with concomitant chronic obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD).

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Morales D.R.
        • Jackson C.
        • Lipworth B.J.
        • et al.
        Adverse respiratory effect of acute beta-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials.
        Chest. 2014; 145: 779-786
        • Salpeter S.
        • Ormiston T.
        • Salpeter E.
        Cardioselective beta-blockers for chronic obstructive pulmonary disease.
        Cochrane Database Syst Rev. 2005; CD003566
        • Salpeter S.R.
        • Ormiston T.M.
        • Salpeter E.E.
        Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.
        Ann Intern Med. 2002; 137: 715-725
        • Hanania N.A.
        • Singh S.
        • El-Wali R.
        • et al.
        The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study.
        Pulm Pharmacol Ther. 2008; 21: 134-141
        • Short P.M.
        • Lipworth S.I.
        • Elder D.H.
        • et al.
        Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study.
        BMJ. 2011; 342: d2549
        • Du Q.
        • Sun Y.
        • Ding N.
        • et al.
        Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies.
        PLoS One. 2014; 9e113048
        • Lipworth B.J.
        • Williamson P.A.
        Beta blockers for asthma: a double-edged sword.
        Lancet. 2009; 373: 104-105
        • Short P.M.
        • Williamson P.A.
        • Anderson W.J.
        • et al.
        Randomized placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma.
        Am J Respir Crit Care Med. 2013; 187: 1308-1314
        • Bond R.A.
        The intrinsic bias of generalizations.
        Am J Respir Crit Care Med. 2014; 189: 359
        • Walker J.K.
        • Penn R.B.
        • Hanania N.A.
        • et al.
        New perspectives regarding beta(2)-adrenoceptor ligands in the treatment of asthma.
        Br J Pharmacol. 2011; 163: 18-28